DeepMed Research

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.eortc.be

Clinical Trials

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Phase 2

Terminated

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Cetuximab
Drug: 5-fluorouracil
Drug: leucovorin

First Posted Date: 2012-01-31

Last Posted Date: 2016-06-10

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 5

Registration Number: NCT01522612

Locations: 🇨🇾
Bank Of Cyprus Oncology Centre, Nicosia, Cyprus
🇧🇪
AZ Turnhout - Campus Sint Elisabeth, Turnhout, Belgium
🇪🇸
Hospital General Vall D'Hebron, Barcelona, Spain

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Phase 2

Terminated

Conditions: Colorectal Cancer Metastatic
Liver Metastases
KRAS Wild Type Colorectal Cancer

Interventions: Drug: FOLFOX6
Procedure: Surgery
Biological: Bevacizumab
Biological: Panitumumab

First Posted Date: 2012-01-11

Last Posted Date: 2016-10-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 44

Registration Number: NCT01508000

Locations: 🇧🇪
AZ Groeninge Kortrijk - Campus Kennedylaan, Kortrijk, Belgium
🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇫🇷
CHU Ambroise Pare, Boulogne Billancourt, France

and more 22 locations

Adjuvant PEG Intron in Ulcerated Melanoma

Phase 3

Conditions: Ulcerated Melanomas

Interventions: Biological: PEG IFN alfa-2b

First Posted Date: 2012-01-02

Last Posted Date: 2019-03-04

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1200

Registration Number: NCT01502696

Locations: 🇵🇹
Hospital Distrital De Santarem, Santarem, Portugal
🇩🇪
Universitaetsklinikum, Essen, Germany
🇩🇪
Universitaetsklinikum Heidelberg - Hautklinik / Dermatologic Department, Heidelberg, Germany

and more 54 locations

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2011-07-26

Last Posted Date: 2023-12-11

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 88

Registration Number: NCT01402271

Locations: 🇪🇸
Hospital Clínico Universitario San Carlos, Madrid, Spain
🇳🇱
Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
🇧🇪
C.H.U. Sart-Tilman, Liege, Belgium

and more 6 locations

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Phase 3

Withdrawn

Conditions: Lymphoma

First Posted Date: 2011-07-01

Last Posted Date: 2015-01-21

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT01386398

Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2011-04-28

Last Posted Date: 2023-04-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 266

Registration Number: NCT01344018

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
🇳🇴
Radium Hospitalet, Oslo, Norway
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium

and more 34 locations

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2011-03-28

Last Posted Date: 2012-07-16

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 160

Registration Number: NCT01324063

Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998

Conditions: Cancer Survivor
Leukemia
Long-term Effects Secondary to Cancer Therapy in Children

First Posted Date: 2011-02-17

Last Posted Date: 2011-09-16

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 3138

Registration Number: NCT01298388

Bevacizumab and Lomustine for Recurrent GBM

Phase 3

Completed

Conditions: Glioblastoma Multiforme
Cognition Disorders
Disability Evaluation

Interventions: Biological: bevacizumab
Genetic: DNA methylation analysis
Drug: lomustine
Other: laboratory biomarker analysis
Procedure: cognitive assessment
Procedure: quality-of-life assessment

First Posted Date: 2011-02-07

Last Posted Date: 2021-02-15

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 592

Registration Number: NCT01290939

Locations: 🇳🇱
Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
🇳🇱
Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands

Empirical Versus Preemptive Antifungal Therapy

Phase 3

Completed

Conditions: Fungal Infection
Leukemia
Myelodysplastic Syndromes

Interventions: Drug: caspofungin acetate

First Posted Date: 2011-02-02

Last Posted Date: 2023-12-11

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 556

Registration Number: NCT01288378

Locations: 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇧🇪
C.H.U. Sart-Tilman, Liège, Belgium
🇫🇷
Hopital Universitaire Hautepierre, Strasbourg, France

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy